Browsing by Author "Scheepers, Paul"
Now showing 1 - 5 of 5
Results Per Page
Sort Options
- Developing human biomonitoring as a 21st century toolbox within the European exposure science strategy 2020-2030Publication . Zare Jeddi, Maryam; Hopf, Nancy B.; Louro, Henriqueta; Viegas, Susana; Galea, Karen S.; Pasanen-Kase, Robert; Santonen, Tiina; Mustieles, Vicente; Fernandez, Mariana F.; Verhagen, Hans; Bopp, Stephanie K.; Antignac, Jean Philippe; David, Arthur; Mol, Hans; Barouki, Robert; Audouze, Karine; Duca, Radu-Corneliu; Fantke, Peter; Scheepers, Paul; Ghosh, Manosij; Van Nieuwenhuyse, An; Lobo Vicente, Joana; Trier, Xenia; Rambaud, Loïc; Fillol, Clémence; Denys, Sebastien; Conrad, André; Kolossa-Gehring, Marike; Paini, Alicia; Arnot, Jon; Schulze, Florian; Jones, Kate; Sepai, Ovnair; Ali, Imran; Brennan, Lorraine; Benfenati, Emilio; Cubadda, Francesco; Mantovani, Alberto; Bartonova, Alena; Connolly, Alison; Slobodnik, Jaroslav; Bruinen de Bruin, Yuri; van Klaveren, Jacob; Palmen, Nicole; Dirven, Hubert; Husøy, Trine; Thomsen, Cathrine; Virgolino, Ana; Röösli, Martin; Gant, Tim; von Goetz, Natalie; Bessems, JosHuman biomonitoring (HBM) is a crucial approach for exposure assessment, as emphasised in the European Commission’s Chemicals Strategy for Sustainability (CSS). HBM can help to improve chemical policies in five major key areas: (1) assessing internal and aggregate exposure in different target populations; 2) assessing exposure to chemicals across life stages; (3) assessing combined exposure to multiple chemicals (mixtures); (4) bridging regulatory silos on aggregate exposure; and (5) enhancing the effectiveness of risk management measures. In this strategy paper we propose a vision and a strategy for the use of HBM in chemical regulations and public health policy in Europe and beyond. We outline six strategic objectives and a roadmap to further strengthen HBM approaches and increase their implementation in the regulatory risk assessment of chemicals to enhance our understanding of exposure and health impacts, enabling timely and targeted policy interventions and risk management. These strategic objectives are: 1) further development of sampling strategies and sample preparation; 2) further development of chemical-analytical HBM methods; 3) improving harmonisation throughout the HBM research life cycle; 4) further development of quality control / quality assurance throughout the HBM research life cycle; 5) obtain sustained funding and reinforcement by legislation; and 6) extend target-specific communication with scientists, policymakers, citizens and other stakeholders. HBM approaches are essential in risk assessment to address scientific, regulatory and societal challenges. HBM requires full and strong support from the scientific and regulatory domain to reach its full potential in public and occupational health assessment and in regulatory decision-making.
- HBM4EU - Deliverable Report D 6.2. Revised set of key indicatorsPublication . Reynders, Hans; Van Campenhout, Karen; Mampaey, Maja; Gilles, Liese; Colles, Ann; Baken, Kirsten; Bessems, Jos; Schoeters, Greet; Ay, Derya; Lobo Vicente, Joana; Ganzleben, Catherine; Isidro, Glória; Louro, Henriqueta; Silva, Maria João; Uhl, Maria; Ubong, Dorothy; Sepai, Ovnair; Tarroja, Elena; Persoz, Charles; Barouki, Robert; Kobosil, Nicole; David, Madlen; Appel, Petra; Kolossa, Marike; Coertjens, Dries; Crabbé, Ann; Loots, Ilse; Covaci, Adrian; Antignac, Jean-Philippe; Debrauwer, Laurent; Fernandez, Mariana; Berglund, Marika; Blaha, Ludek; Esteban López, Marta; Scheepers, Paul; Tolonen, Hanna; Nørager., SofieThe current deliverable describes the process of revision of the first list of indicators (published in June 2017 as D6.1.) and presents the indicator leaflets ((see attachment 1) that link key results of HBM4EU to the objectives of the project as laid down in the description of action. These indicator leaflets already contain a lot of results on the revised list of indicators, and give very valuable information on the progress of HBM4EU in relation to the specific goals of the project. Combining the information from these leaflets in the frame of expected impacts will allow us to put forward conclusions towards impact and sustainability of HBM4EU. As such, this restructured list answers to the main comments on the first list of indicators from the task 6.5 partners, the Management Board, the Governing Board and the EU Policy Board, in concretu to: • Drastically reduce the number of indicators from 48 indicators (including 9 internal indicators) on the first list to 28 indicators on the revised list without losing essential information. Moreover by bundling related indicators we now have 22 indicator leaflets (and 1 overview leaflet); • Make the relationship between the indicators and the goals of HBM4EU more clear by structuring the list of indicators according to the overarching objectives and specific goals; • Use the indicators to say something about the impact of the HBM4EU project: the indicator leaflets were used to give input for the impact section of the periodic technical reporting 2018 to describe the progress made for the 5 expected impacts of HBM4EU. This exercise will be continued and ameliorated in the 2019 periodic technical reporting as more indicator leaflets will be available compared to 2018; • Link the indicators with the work on sustainability of HBM in Europe: the indicators were presented at the sustainability workshop in Paris. Participants indicated that they think the leaflets will be useful for institutional discussions, national hub meetings, meetings with policy makers and other meetings and that they would like to use them as soon as they are available. The added value of having indicators of success, is to monitor the implementation and achieved impact of HBM4EU. This will allow for a more efficient tracking of achieved goals. This deliverable will help to further optimize and revise the first set of indicators to monitor the implementation of the HBM4EU and the achieved impact. The indicators of success are written in a clear language, they are concise and capture the main achievements in the list of indicators that has been agreed amongst the partners. Therefore, they can be easily used by all partners across the consortium, the EU Policy Board and our HBM4EU ambassador Thomas Jackl.
- HBM4EU Chromates Study - Genotoxicity and Oxidative Stress Biomarkers in Workers Exposed to Hexavalent ChromiumPublication . Tavares, Ana; Aimonen, Kukka; Ndaw, Sophie; Fučić, Aleksandra; Catalán, Julia; Duca, Radu Corneliu; Godderis, Lode; Gomes, Bruno C.; Janasik, Beata; Ladeira, Carina; Louro, Henriqueta; Namorado, Sónia; Nieuwenhuyse, An Van; Norppa, Hannu; Scheepers, Paul; Ventura, Célia; Verdonck, Jelle; Viegas, Susana; Wasowicz, Wojciech; Santonen, Tiina; Silva, M.J.; on behalf of the HBM4EU Chromates Study TeamA study was conducted within the European Human Biomonitoring Initiative (HBM4EU) to characterize occupational exposure to Cr(VI). Herein we present the results of biomarkers of genotoxicity and oxidative stress, including micronucleus analysis in lymphocytes and reticulocytes, the comet assay in whole blood, and malondialdehyde and 8-oxo-2'-deoxyguanosine in urine. Workers from several Cr(VI)-related industrial activities and controls from industrial (within company) and non-industrial (outwith company) environments were included. The significantly increased genotoxicity (p = 0.03 for MN in lymphocytes and reticulocytes; p < 0.001 for comet assay data) and oxidative stress levels (p = 0.007 and p < 0.001 for MDA and 8-OHdG levels in pre-shift urine samples, respectively) that were detected in the exposed workers over the outwith company controls suggest that Cr(VI) exposure might still represent a health risk, particularly, for chrome painters and electrolytic bath platers, despite the low Cr exposure. The within-company controls displayed DNA and chromosomal damage levels that were comparable to those of the exposed group, highlighting the relevance of considering all industry workers as potentially exposed. The use of effect biomarkers proved their capacity to detect the early biological effects from low Cr(VI) exposure, and to contribute to identifying subgroups that are at higher risk. Overall, this study reinforces the need for further re-evaluation of the occupational exposure limit and better application of protection measures. However, it also raised some additional questions and unexplained inconsistencies that need follow-up studies to be clarified.
- Setting up a collaborative European Human biological monitoring study on occupational exposure to Hexavalent ChromiumPublication . Santonen, Tiina; Alimonti, Alessandro; Bocca, Beatrice; Duca, Radu Corneliu; Galea, Karen S.; Godderis, Lode; Göen, Thomas; Gomes, Bruno; Hanser, Ogier; Iavicoli, Ivo; Janasik, Beata; Jones, Kate; Kiilunen, Mirja; Koch, Holger M.; Leese, Liz; Leso, Veruscka; Louro, Henriqueta; Ndaw, Sophie; Porras, Simo P.; Robert, Alain; Ruggieri, Flavia; Scheepers, Paul; Silva, Maria João; Viegas, Susana; Wasowicz, Wojciech; Castano, Argelia; Sepai, OvnairBackground: The EU human biomonitoring initiative, HBM4EU, aims to co-ordinate and advance human biomonitoring across Europe and develop new approaches for biomonitoring. Hexavalent chromium (Cr(VI)) is an important occupational carcinogen, which compounds are currently authorized in Europe. In addition, a binding limit value for occupational exposure to Cr(VI) has been recently agreed in EU. These regulatory actions emphasize the need for EU-wide data on exposure and sensitive biomarkers to assess the exposure. Here we describe the design of the multinational, collaborative project to support management of occupational exposure to Cr(VI). Methods: The study involves eight European countries and aims to recruit 400 workers performing Cr(VI) surface treatment or stainless steel welding. In addition to urinary chromium (U-Cr), exhaled breath condensate (EBC) and blood samples are collected for the analysis of Cr(VI)/Cr. Exposure data will be complemented with data on effect markers. Personal air and wipe samples are collected in parallel to help interpretation of biomonitoring results. Standardized questionnaires are used to collect contextual data, and samplings are done following the standard operational procedures developed to support standardization. Results: This occupational Cr(VI) study is the first that will be performed concurrently in multiple European countries using harmonized protocols for data gathering, sampling and analysis. Combining national standardized surveys the power of the study and the strength of the findings is greatly enhanced. Samplings are currently on-going and include companies ranging from micro-sized companies to large international companies. Final results are expected by the end of 2020. The presentation covers the background data on the tasks covered and the available external exposure data. Conclusions: Using this unique set-up including multiple countries and harmonized protocols we expect to create more comprehensive data for EU decision making. The data allows also the assessment of the feasibility of different biomarkers in the biomonitoring of Cr(VI).
- The HBM4EU e-waste study: exploratory survey of worker’s exposure to toxic contaminantsPublication . Scheepers, Paul; Viegas, S.; Duca, R.C.; Cseresznye, A; Cleys, P.; Covaci, A.; Goën, T.; Galea, K.S.; Godderis, L.; Hardy, E.; Leese, E.; Louro, Henriqueta; Mahiout, S.; Ndaw, S; Poels, K.; Silva, Maria João; Verdonck, J.; Porras, S.; Santonen, T.; HBM4EU E-waste Study TeamSo far, human biomonitoring (HBM) has not been much used to study exposure of workers involved in the processing of e-waste in the EU. In this study we aimed to explore exposures of workers to chemical contaminants, contribute to raise awareness of potential hazards and to further improve work practices. The study was conducted in eight European counties in a target population of 195 exposed and 73 controls. Biomarkers of exposure were used for selected metals and organic contaminants. Occupational hygiene sampling methods and contextual information were collected to facilitate the interpretation of the biomarker results. We found somewhat elevated exposures in workers for cadmium and mercury in blood and urine compared to controls. Blood analysis indicated high lead levels in post-shift compared to pre-shift in battery workers. Some urinary phthalate metabolite levels indicated a contribution from work-related exposures and were more pronounced in battery workers. Only small differences were observed in urinary excretion before and after the shift for organophosphorus flame retardants. Brominated flame retardant and PCB serum levels were in the range of general population background. From this exploratory study we conclude that more studies are needed to better understand chemical exposure in the processing of e-waste.